BDNF Gene Polymorphism and Antidepressants Treatment
Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression
1 other identifier
interventional
188
1 country
1
Brief Summary
The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 depression
Started Jul 2006
Longer than P75 for phase_4 depression
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 28, 2006
CompletedFirst Posted
Study publicly available on registry
March 30, 2006
CompletedStudy Start
First participant enrolled
July 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2012
CompletedDecember 23, 2025
December 1, 2025
5.9 years
March 28, 2006
December 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Score on Montgomery and Asberg Depression Rating Scale (MADRS)
At 3 weeks and 6 weeks
Study Arms (1)
Escitalopram
EXPERIMENTALTreatment response after 3 and 6 weeks
Interventions
Eligibility Criteria
You may qualify if:
- Patient suffering a severe depressive episode (according to DSM-IV), evolving since at least 2 weeks before entering the study
- Age superior to 18 years
- Caucasian type
- In absence of any medicinal treatment that could enhance depression: methyldopa, beta-blockers, reserpine,
- In absence of hypothyroidia or anaemia
- Without comorbidity that could affect therapy response : e.g. food disorder, substance abuse or dependence syndrome
You may not qualify if:
- \- Will be excluded from the study the patients for which a modification of the depression diagnosis (according to the DSM-IV criteria) takes place during the period of study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Tourslead
- H. Lundbeck A/Scollaborator
Study Sites (1)
CPU CHRU de Tours
Tours, 37044, France
Related Publications (1)
El-Hage W, Vourc'h P, Gaillard P, Leger J, Belzung C, Ibarguen-Vargas Y, Andres CR, Camus V. The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients. Psychopharmacology (Berl). 2015 Feb;232(3):575-81. doi: 10.1007/s00213-014-3694-z. Epub 2014 Jul 31.
PMID: 25074447RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wissam EL HAGE, MD, PhD
UNIVERSITY HOSPITAL OF TOURS
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2006
First Posted
March 30, 2006
Study Start
July 1, 2006
Primary Completion
June 1, 2012
Study Completion
June 1, 2012
Last Updated
December 23, 2025
Record last verified: 2025-12